ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy

Millie Das, Jonathan Riess, Paul Frankel, Erich Schwartz, Robyn Bennis, H. Ben Hsieh, Xiaohe Liu, Janey C. Ly, Lisa Zhou, Jorge J. Nieva, Heather A. Wakelee, Richard H. Bruce

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose: To utilize a novel circulating tumor cell (CTC) technology to quantify ERCC1 expression on CTCs and determine whether ERCC1 expression levels predict efficacy of platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). Experimental design: ERCC1 expression was measured in 17 metastatic NSCLC patients who received platinum-based therapy and had ≥2 intact CTCs with acceptable ERCC1 expression assay results. ERCC1 levels were determined from average expression on individual CTCs in each sample. Progression-free survival (PFS) was calculated from the date of therapy initiation. Results: PFS decreased with increasing ERCC1 expression (p<0.04, F-test, linear regression). Lack of ERCC1 expression was associated with longer PFS (266 days versus 172 days, log-rank, p<0.02) in a Kaplan-Meier analysis using ERCC expression level of 1 as a cutoff (range 0-30). The difference in survival was statistically significant with a hazard ratio of 4.20 (95% CI 1.25-14.1, p<0.02, log-rank). PFS was also observed to decrease with increased cytokeratin (CK) expression (p<0.01 long-rank (Cox regression) and F-test (linear regression)). The hazard ratio is 4.38 (95% CI 1.76-10.9) for each log-change in CK value until progression was noted on imaging. Conclusion: Low expression of ERCC1 on CTCs correlates with PFS in patients with metastatic NSCLC receiving platinum-based therapy.

Original languageEnglish (US)
Pages (from-to)421-426
Number of pages6
JournalLung Cancer
Volume77
Issue number2
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Platinum
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Drug Therapy
Keratins
Linear Models
Kaplan-Meier Estimate
Research Design
Therapeutics
Technology
Survival

Keywords

  • Circulating tumor cells
  • ERCC1
  • Non-small-cell lung cancer
  • Platinum-based chemotherapy
  • Prognostic diagnostic

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. / Das, Millie; Riess, Jonathan; Frankel, Paul; Schwartz, Erich; Bennis, Robyn; Hsieh, H. Ben; Liu, Xiaohe; Ly, Janey C.; Zhou, Lisa; Nieva, Jorge J.; Wakelee, Heather A.; Bruce, Richard H.

In: Lung Cancer, Vol. 77, No. 2, 08.2012, p. 421-426.

Research output: Contribution to journalArticle

Das, Millie ; Riess, Jonathan ; Frankel, Paul ; Schwartz, Erich ; Bennis, Robyn ; Hsieh, H. Ben ; Liu, Xiaohe ; Ly, Janey C. ; Zhou, Lisa ; Nieva, Jorge J. ; Wakelee, Heather A. ; Bruce, Richard H. / ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. In: Lung Cancer. 2012 ; Vol. 77, No. 2. pp. 421-426.
@article{ab8ad9eaeb194f4dbd11f093c9c83e41,
title = "ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy",
abstract = "Purpose: To utilize a novel circulating tumor cell (CTC) technology to quantify ERCC1 expression on CTCs and determine whether ERCC1 expression levels predict efficacy of platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). Experimental design: ERCC1 expression was measured in 17 metastatic NSCLC patients who received platinum-based therapy and had ≥2 intact CTCs with acceptable ERCC1 expression assay results. ERCC1 levels were determined from average expression on individual CTCs in each sample. Progression-free survival (PFS) was calculated from the date of therapy initiation. Results: PFS decreased with increasing ERCC1 expression (p<0.04, F-test, linear regression). Lack of ERCC1 expression was associated with longer PFS (266 days versus 172 days, log-rank, p<0.02) in a Kaplan-Meier analysis using ERCC expression level of 1 as a cutoff (range 0-30). The difference in survival was statistically significant with a hazard ratio of 4.20 (95{\%} CI 1.25-14.1, p<0.02, log-rank). PFS was also observed to decrease with increased cytokeratin (CK) expression (p<0.01 long-rank (Cox regression) and F-test (linear regression)). The hazard ratio is 4.38 (95{\%} CI 1.76-10.9) for each log-change in CK value until progression was noted on imaging. Conclusion: Low expression of ERCC1 on CTCs correlates with PFS in patients with metastatic NSCLC receiving platinum-based therapy.",
keywords = "Circulating tumor cells, ERCC1, Non-small-cell lung cancer, Platinum-based chemotherapy, Prognostic diagnostic",
author = "Millie Das and Jonathan Riess and Paul Frankel and Erich Schwartz and Robyn Bennis and Hsieh, {H. Ben} and Xiaohe Liu and Ly, {Janey C.} and Lisa Zhou and Nieva, {Jorge J.} and Wakelee, {Heather A.} and Bruce, {Richard H.}",
year = "2012",
month = "8",
doi = "10.1016/j.lungcan.2012.04.005",
language = "English (US)",
volume = "77",
pages = "421--426",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy

AU - Das, Millie

AU - Riess, Jonathan

AU - Frankel, Paul

AU - Schwartz, Erich

AU - Bennis, Robyn

AU - Hsieh, H. Ben

AU - Liu, Xiaohe

AU - Ly, Janey C.

AU - Zhou, Lisa

AU - Nieva, Jorge J.

AU - Wakelee, Heather A.

AU - Bruce, Richard H.

PY - 2012/8

Y1 - 2012/8

N2 - Purpose: To utilize a novel circulating tumor cell (CTC) technology to quantify ERCC1 expression on CTCs and determine whether ERCC1 expression levels predict efficacy of platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). Experimental design: ERCC1 expression was measured in 17 metastatic NSCLC patients who received platinum-based therapy and had ≥2 intact CTCs with acceptable ERCC1 expression assay results. ERCC1 levels were determined from average expression on individual CTCs in each sample. Progression-free survival (PFS) was calculated from the date of therapy initiation. Results: PFS decreased with increasing ERCC1 expression (p<0.04, F-test, linear regression). Lack of ERCC1 expression was associated with longer PFS (266 days versus 172 days, log-rank, p<0.02) in a Kaplan-Meier analysis using ERCC expression level of 1 as a cutoff (range 0-30). The difference in survival was statistically significant with a hazard ratio of 4.20 (95% CI 1.25-14.1, p<0.02, log-rank). PFS was also observed to decrease with increased cytokeratin (CK) expression (p<0.01 long-rank (Cox regression) and F-test (linear regression)). The hazard ratio is 4.38 (95% CI 1.76-10.9) for each log-change in CK value until progression was noted on imaging. Conclusion: Low expression of ERCC1 on CTCs correlates with PFS in patients with metastatic NSCLC receiving platinum-based therapy.

AB - Purpose: To utilize a novel circulating tumor cell (CTC) technology to quantify ERCC1 expression on CTCs and determine whether ERCC1 expression levels predict efficacy of platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). Experimental design: ERCC1 expression was measured in 17 metastatic NSCLC patients who received platinum-based therapy and had ≥2 intact CTCs with acceptable ERCC1 expression assay results. ERCC1 levels were determined from average expression on individual CTCs in each sample. Progression-free survival (PFS) was calculated from the date of therapy initiation. Results: PFS decreased with increasing ERCC1 expression (p<0.04, F-test, linear regression). Lack of ERCC1 expression was associated with longer PFS (266 days versus 172 days, log-rank, p<0.02) in a Kaplan-Meier analysis using ERCC expression level of 1 as a cutoff (range 0-30). The difference in survival was statistically significant with a hazard ratio of 4.20 (95% CI 1.25-14.1, p<0.02, log-rank). PFS was also observed to decrease with increased cytokeratin (CK) expression (p<0.01 long-rank (Cox regression) and F-test (linear regression)). The hazard ratio is 4.38 (95% CI 1.76-10.9) for each log-change in CK value until progression was noted on imaging. Conclusion: Low expression of ERCC1 on CTCs correlates with PFS in patients with metastatic NSCLC receiving platinum-based therapy.

KW - Circulating tumor cells

KW - ERCC1

KW - Non-small-cell lung cancer

KW - Platinum-based chemotherapy

KW - Prognostic diagnostic

UR - http://www.scopus.com/inward/record.url?scp=84863775812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863775812&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2012.04.005

DO - 10.1016/j.lungcan.2012.04.005

M3 - Article

C2 - 22555222

AN - SCOPUS:84863775812

VL - 77

SP - 421

EP - 426

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -